Immunity in strain 2 guinea-pigs inoculated with vaccinia virus recombinants expressing varicella-zoster virus glycoproteins I, IV, V or the protein product of the immediate early gene 62.
The immunogenicity of specific varicella-zoster virus (VZV) proteins, with emphasis upon cell-mediated immune responses, was evaluated by immunizing strain 2 guinea-pigs with vaccinia virus recombinants that express gpI (vac-gpI), gpIV (vac-gpIV) and gpV (vac-gpV) or the IE-62 protein (vac-IE-62). Vac-gpI elicited the highest initial mean T cell proliferation response [stimulation index (S.I.) 3.8 +/- 0.9 S.E.M.] whereas inoculation with vac-gpV produced the lowest primary T cell response (S.I. 2.5 +/- 1.1 S.E.M.). T cell proliferation was detected for a shorter period after immunization with vac-gpV compared to vac-gpI, vac-gpIV or vac-IE-62. A comparison of the immunogenicity of vac-gpI and vac-IE-62 with the same proteins prepared by immunoaffinity purification showed that immunization with these proteins in either form elicited virus-specific IgG antibodies and T cell recognition. The presence or absence of IgG antibodies to the IE-62 protein was used to assess protection against challenge with guinea-pig cell-adapted infectious VZV in animals that had been inoculated with vac-gpI, vac-gpIV or vac-gpV. Immunization with vac-gpI and vac-gpIV restricted VZV replication but all animals given vac-gpV developed antibodies to IE-62 after challenge with infectious VZV. Priming of the T lymphocyte response was observed in all animals immunized with VZV-vaccinia virus recombinants after subsequent exposure to infectious VZV. These experiments with VZV vac-gpI, vac-gpIV and vac-gpV in guinea-pigs suggest variability in the capacity of herpesviral glycoproteins to elicit cell-mediated immunity in vivo. Induction of virus-specific immunity using IE-62 means that this major tegument protein of VZV could be a useful component for vaccine development.
Lowry
P W
PW
Department of Pediatrics, Stanford University School of Medicine, California 94305.
Solem
S
S
Watson
B N
BN
Koropchak
C M
CM
Thackray
H M
HM
Kinchington
P R
PR
Ruyechan
W T
WT
Ling
P
P
Hay
J
J
Arvin
A M
AM
D000818:Animals; D006168:Guinea Pigs / Q000276:immunology*; D006562:Herpes Zoster / Q000276:immunology*; D014645:Herpesvirus 3, Human / Q000235:genetics / Q000276:immunology*; D017874:Immediate-Early Proteins; D007111:Immunity, Cellular / Q000276:immunology*; D016233:Immunotherapy, Active / Q000379:methods*; D008213:Lymphocyte Activation; D011994:Recombinant Proteins / Q000096:biosynthesis / Q000276:immunology; D013601:T-Lymphocytes; D015534:Trans-Activators; D014616:Vaccinia virus / Q000235:genetics; D014759:Viral Envelope Proteins / Q000096:biosynthesis / Q000276:immunology; D014764:Viral Proteins / Q000096:biosynthesis / Q000235:genetics / Q000276:immunology*
C074221:IE62 protein, Human herpesvirus 3; D017874:Immediate-Early Proteins; D011994:Recombinant Proteins; D015534:Trans-Activators; D014759:Viral Envelope Proteins; D014764:Viral Proteins; C056913:glycoprotein E, varicella-zoster virus; C070916:glycoprotein IV, varicella-zoster virus; C070744:glycoprotein V, varicella-zoster virus